Clinical Trials and Research

AbstractWild-type transthyretin cardiac amyloidosis (ATTRwt) is an underrecognized cause of heart failure that often mimics hypertensive or nonischemic…

AbstractBackgroundPathogenic transthyretin (TTR) variants, such as V142I, demonstrate incomplete, age-dependent penetrance and may be present in patients without…

AbstractTransthyretin amyloidosis (ATTR) is a rare, progressive, and fre- quently under-recognized systemic disease whose early clinical manifes- tations may…

TOPLINE:In patients newly diagnosed with cardiac amyloidosis (CA), continuous rhythm monitoring using implantable loop recorders found that clinically significant…

Cardiovascular diseases could be among the world’s first medical conditions to be treated by changing a patient’s genes. If ongoing phase 3 trials succeed, gene…

AbstractBackground and Purpose: Transthyretin (ATTR) amyloidosis, including wild-type (ATTRwt) and hereditary (ATTRv) forms, is a rare but increasingly recognized…

Introduction. Heart failure (HF) is a leading cause of hospitalization in Internal Medicine and HF with preserved ejection fraction (HFpEF) accounts for…

TARRYTOWN, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 1/2 LINKER-AL2…

AbstractBackgroundIn the phase III Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (HELIOS-B), vutrisiran significantly…

AbstractThe therapeutic landscape for systemic immunoglobulin light chain (AL) amyloidosis has been revolutionized by daratumumab-based regimens, achieving 76% 5-…